JAK1 and acute lymphoblastic leukemia: JAK3 is the most frequently mutated component of the IL-7 signaling pathway, with mutations identified in up to 16% of T-ALL, while JAK1 alterations are rather rare and mainly found in cases that also carry JAK3 or IL7R mutations.